Tags

Type your tag names separated by a space and hit enter

Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.

Abstract

PURPOSE

The objective of this study was to compare the quality of life (QoL) of ovarian cancer patients treated with paclitaxel/carboplatin (TC) versus paclitaxel/cisplatin (PT) and to determine the impact of treatment toxicity on the various QoL domains.

PATIENTS AND METHODS

In this phase III trial, 798 patients with ovarian cancer stages IIB-IV were randomly assigned to receive TC or PT. The primary end point was progression-free survival; secondary end points included toxicity, QoL, and response to treatment. Patients completed the European Organisation for Research and Treatment of Cancer QLQ-C30 before treatment, within 3 days before the second and the fourth chemotherapy cycle, and 3 weeks after completion of chemotherapy.

RESULTS

Previously reported data showed that patients undergoing TC or PT did not differ in progression-free survival and overall survival. However, the TC arm was superior, indicating a better overall QoL compared with the PT arm. Controlling for toxicity and age, a significant treatment by assessment time interaction was found for four QoL functioning scales and three symptoms scales. Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm. Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT.

CONCLUSION

The TC regimen achieved better QoL outcomes compared with the PT regimen. Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Obstetrics and Gynecology, University Graz, Graz, Austria. elfriede.greimel@meduni-graz.at

    , , , , ,

    Source

    MeSH

    Adult
    Aged
    Analysis of Variance
    Antineoplastic Agents, Phytogenic
    Antineoplastic Combined Chemotherapy Protocols
    Austria
    Carboplatin
    Cisplatin
    Disease-Free Survival
    Drug Administration Schedule
    Female
    Germany
    Humans
    Infusions, Intravenous
    Middle Aged
    Neoplasm Staging
    Ovarian Neoplasms
    Paclitaxel
    Quality of Life
    Surveys and Questionnaires
    Survival Analysis
    Treatment Outcome

    Pub Type(s)

    Clinical Trial, Phase III
    Journal Article
    Multicenter Study
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    16446330

    Citation

    Greimel, Elfriede R., et al. "Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/paclitaxel Versus Carboplatin/paclitaxel." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 24, no. 4, 2006, pp. 579-86.
    Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol. 2006;24(4):579-86.
    Greimel, E. R., Bjelic-Radisic, V., Pfisterer, J., Hilpert, F., Daghofer, F., & du Bois, A. (2006). Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 24(4), pp. 579-86.
    Greimel ER, et al. Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/paclitaxel Versus Carboplatin/paclitaxel. J Clin Oncol. 2006 Feb 1;24(4):579-86. PubMed PMID: 16446330.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. AU - Greimel,Elfriede R, AU - Bjelic-Radisic,Vesna, AU - Pfisterer,Jacobus, AU - Hilpert,Felix, AU - Daghofer,Fedor, AU - du Bois,Andreas, AU - ,, PY - 2006/2/1/pubmed PY - 2006/2/14/medline PY - 2006/2/1/entrez SP - 579 EP - 86 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J. Clin. Oncol. VL - 24 IS - 4 N2 - PURPOSE: The objective of this study was to compare the quality of life (QoL) of ovarian cancer patients treated with paclitaxel/carboplatin (TC) versus paclitaxel/cisplatin (PT) and to determine the impact of treatment toxicity on the various QoL domains. PATIENTS AND METHODS: In this phase III trial, 798 patients with ovarian cancer stages IIB-IV were randomly assigned to receive TC or PT. The primary end point was progression-free survival; secondary end points included toxicity, QoL, and response to treatment. Patients completed the European Organisation for Research and Treatment of Cancer QLQ-C30 before treatment, within 3 days before the second and the fourth chemotherapy cycle, and 3 weeks after completion of chemotherapy. RESULTS: Previously reported data showed that patients undergoing TC or PT did not differ in progression-free survival and overall survival. However, the TC arm was superior, indicating a better overall QoL compared with the PT arm. Controlling for toxicity and age, a significant treatment by assessment time interaction was found for four QoL functioning scales and three symptoms scales. Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm. Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT. CONCLUSION: The TC regimen achieved better QoL outcomes compared with the PT regimen. Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/16446330/Randomized_study_of_the_Arbeitsgemeinschaft_Gynaekologische_Onkologie_Ovarian_Cancer_Study_Group_comparing_quality_of_life_in_patients_with_ovarian_cancer_treated_with_cisplatin/paclitaxel_versus_carboplatin/paclitaxel_ L2 - http://ascopubs.org/doi/full/10.1200/JCO.2005.02.4067?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -